NCT07197957Recruiting
Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
BayCare Health System
Start Date
3/11/2025
Completion Date
2/28/2027
Summary
To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).
Detailed Description
The primary objective of this study is to evaluate the clinical utility of Cystatin C in early detection of contrast-induced AKI. To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Subjects ages 18 years and above
* Inpatients with CKD (Figure 1)
* Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
* Pre and post contrast available
* All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.
Exclusion Criteria:
* Preexisting dialysis
* Patients under the age of 18 years
* Pregnancy
* Incarcerated individuals
* Patients with impaired cognition and unable to follow consent procedures
* Recent exposure to CM (within 2 days before/after procedure)
* Cardiac shock
* Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
Conditions
Acute Kidney Injury
Locations
Morton Plant Hospital
Clearwater, Florida 33756
United States
Morton Plant North Bay Hospital
New Port Richey, Florida 34652
United States
Mease Countryside Hospital
Safety Harbor, Florida 34695
United States
St. Anthony's Hospital
St. Petersburg, Florida 33705
United States